IMMUNOTHERAPY USING ALLO-NKT CELLS, CELLS FOR IMMUNOTHERAPY IN WHICH ALPHA CHAIN OF T-CELL RECEPTOR (TCR) GENE HAS BEEN REARRANGED TO UNIFORM V-ALPHA-J-ALPHA, AND BANKING OF NKT CELLS DERIVED FROM SAID CELLS
The present invention provides an agent for an immunocyte therapy, comprising an NKT cell obtained by differentiating in vitro a cell having the α-chain region of the T cell receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, wherein an administration subject is an allogenic individual having MHC gene loci including at least one locus having a genotype different from that of the NKT cell. In addition, the present invention provides a bank of a human cell or an NKT cell derived from said cell, wherein the α-chain region of a T cell receptor (TCR) gene has been rearranged to uniform Vα-Jα. The agent and cell bank of the present invention are useful for the prophylaxis and/or treatment of cancer, infection, an allergic disease or an autoimmune disease.
